GILEAD SCIENCES SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 268
- Registration Number
- NCT02201901
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
Phase 3
Completed
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: PlaceboDrug: SOF/VEL
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 741
- Registration Number
- NCT02201940
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
Phase 1
Completed
- Conditions
- Hepatitis C Virus Infection
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 101
- Registration Number
- NCT02185794
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
Phase 2
Completed
- Conditions
- Diabetic Kidney Disease
- Interventions
- Drug: SelonsertibDrug: Placebo to match selonsertib
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 334
- Registration Number
- NCT02177786
- Locations
- 🇺🇸
Northwest Louisiana Nephrology, Shreveport, Louisiana, United States
🇺🇸Pines Clinical Research Inc., Pembroke Pines, Florida, United States
🇺🇸Florida Pulmonary Research Institute, Winter Park, Florida, United States
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo to match GS-5745Drug: GS-5745
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT02176876
Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT02175758
Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment
Phase 2
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Tenofovir disoproxil fumarateBiological: GS-4774
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 195
- Registration Number
- NCT02174276
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Kaiser Permanente, Springfield, Virginia, United States
🇺🇸Research and Education, Inc., San Diego, California, United States
Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 162
- Registration Number
- NCT02166047
Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Phase 2
Withdrawn
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Drug: IMMU-132 infusion is administered to participants in one arm for the studyDrug: IMMU-132 plus Carboplatin infusion
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT02161679
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT02136511
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇮🇹Ospedale San Raffaele, Milano, Italy
© Copyright 2025. All Rights Reserved by MedPath